Completed PHASE2 INTERVENTIONAL 1-arm NCT00518453

Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Formulation 2007-2008

A Phase II, Open-Label, Uncontrolled, Single Center Study to Evaluate Safety and Immunogenicity of a Surface Antigen, Inactivated Influenza Vaccine Ph.Eur, Formulation 2007-2008, When Administered to Non-Elderly Adult and Elderly Subjects

Sponsor: Novartis Vaccines

Conditions Influenza

Interventions Surface antigen inactivated influenza vaccine

Updated 5 times since 2017 Last updated: Nov 30, 2016 Started: Jul 31, 2007 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00518453, this PHASE2 trial focuses on Influenza and remains completed. Sponsored by Novartis Vaccines, it has been updated 5 times since 2007, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Vaccines

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Suffolk, United Kingdom